Historical Valuation
Xeris Biopharma Holdings Inc (XERS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.41 is considered Undervalued compared with the five-year average of -6.90. The fair price of Xeris Biopharma Holdings Inc (XERS) is between 5106.86 to 5109.79 according to relative valuation methord. Compared to the current price of 8.17 USD , Xeris Biopharma Holdings Inc is Undervalued By 99.84%.
Relative Value
Fair Zone
5106.86-5109.79
Current Price：8.17
99.84%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Xeris Biopharma Holdings Inc (XERS) has a current Price-to-Book (P/B) ratio of -1413.19. Compared to its 3-year average P/B ratio of -144.52 , the current P/B ratio is approximately 877.85% higher. Relative to its 5-year average P/B ratio of -103.54, the current P/B ratio is about 1264.90% higher. Xeris Biopharma Holdings Inc (XERS) has a Forward Free Cash Flow (FCF) yield of approximately 0.82%. Compared to its 3-year average FCF yield of -15.87%, the current FCF yield is approximately -105.16% lower. Relative to its 5-year average FCF yield of -24.42% , the current FCF yield is about -103.35% lower.
P/B
Median3y
-144.52
Median5y
-103.54
FCF Yield
Median3y
-15.87
Median5y
-24.42
Competitors Valuation Multiple
AI Analysis for XERS
The average P/S ratio for XERS competitors is 9274.34, providing a benchmark for relative valuation. Xeris Biopharma Holdings Inc Corp (XERS.O) exhibits a P/S ratio of 3.41, which is -99.96% above the industry average. Given its robust revenue growth of 37.06%, this premium appears sustainable.
Performance Decomposition
AI Analysis for XERS
1Y
3Y
5Y
Market capitalization of XERS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of XERS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is XERS currently overvalued or undervalued?
Xeris Biopharma Holdings Inc (XERS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.41 is considered Undervalued compared with the five-year average of -6.90. The fair price of Xeris Biopharma Holdings Inc (XERS) is between 5106.86 to 5109.79 according to relative valuation methord. Compared to the current price of 8.17 USD , Xeris Biopharma Holdings Inc is Undervalued By 99.84% .
What is Xeris Biopharma Holdings Inc (XERS) fair value?
XERS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Xeris Biopharma Holdings Inc (XERS) is between 5106.86 to 5109.79 according to relative valuation methord.
How does XERS's valuation metrics compare to the industry average?
The average P/S ratio for XERS's competitors is 9274.34, providing a benchmark for relative valuation. Xeris Biopharma Holdings Inc Corp (XERS) exhibits a P/S ratio of 3.41, which is -99.96% above the industry average. Given its robust revenue growth of 37.06%, this premium appears sustainable.
What is the current P/B ratio for Xeris Biopharma Holdings Inc (XERS) as of Jan 10 2026?
As of Jan 10 2026, Xeris Biopharma Holdings Inc (XERS) has a P/B ratio of -1413.19. This indicates that the market values XERS at -1413.19 times its book value.
What is the current FCF Yield for Xeris Biopharma Holdings Inc (XERS) as of Jan 10 2026?
As of Jan 10 2026, Xeris Biopharma Holdings Inc (XERS) has a FCF Yield of 0.82%. This means that for every dollar of Xeris Biopharma Holdings Inc’s market capitalization, the company generates 0.82 cents in free cash flow.
What is the current Forward P/E ratio for Xeris Biopharma Holdings Inc (XERS) as of Jan 10 2026?
As of Jan 10 2026, Xeris Biopharma Holdings Inc (XERS) has a Forward P/E ratio of 60.39. This means the market is willing to pay $60.39 for every dollar of Xeris Biopharma Holdings Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Xeris Biopharma Holdings Inc (XERS) as of Jan 10 2026?
As of Jan 10 2026, Xeris Biopharma Holdings Inc (XERS) has a Forward P/S ratio of 3.41. This means the market is valuing XERS at $3.41 for every dollar of expected revenue over the next 12 months.